Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2001, the company has made significant strides in developing innovative therapies for rare diseases, particularly in the field of metabolic disorders. Savient is best known for its flagship product, Krystexxa, which offers a unique treatment option for chronic gout, setting it apart in a competitive market. With a focus on research and development, Savient has established a strong market position, catering to patients with unmet medical needs. The company operates primarily in North America, with a commitment to advancing healthcare solutions that improve patient outcomes. Through its dedication to innovation and quality, Savient Pharmaceuticals continues to make a meaningful impact in the biopharmaceutical landscape.
DitchCarbon Score
How does Savient Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Savient Pharmaceuticals, Inc.'s score of 18 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Savient Pharmaceuticals, Inc.'s reported carbon emissions
Savient Pharmaceuticals, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is essential to note that many pharmaceutical companies are increasingly focusing on sustainability and climate commitments, often aligning with industry standards to reduce their environmental impact. As Savient Pharmaceuticals continues to navigate the evolving landscape of climate responsibility, stakeholders may look for future announcements regarding their emissions strategies and sustainability initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Savient Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
